| |
Cancer is an incredibly intricate disease. In recent years, there’s been a shift in how early-phase oncology studies are conducted as adaptive trial designs have become more common. These designs aim to increase the chance of trial success. Read our blog to learn more. Premier Research. Built for Biotech℠ .png)
|
|
Today's Big NewsFeb 23, 2023 |
As Novartis pulls back from legacy sickle cell program, Intellia CEO calls the market 'wide open'
Moderna, on its back foot, reassures investors on flu vaccine after mixed phase 3 data
Layoffs not letting up: Impel, Cybin, EQRx all trim head counts with eyes on saving cash
Prilenia searches for positive signs as oral ALS drug fails to improve disease severity in phase 2
Jounce pounces on exit opportunity, laying off 57% of staff alongside reverse merger with Redx
Capsida reels in another Big Pharma deal, this time diving into eye disease with AbbVie
Graphite pencils out sickle cell therapy after adverse event, cutting half of workforce loose
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
Fallout from Quantum Genomics' phase 3 fail claims top executives as biotech searches for a future
Biocryst hits another hurdle, delays trial for its 1 remaining clinical candidate
Infinity pools resources with MEI Pharma in oncology-focused merger
After a tough year, VBL merges with Notable Labs |
|
March 14-15, 2023 | San Francisco, CA Be in the room with the life sciences industry leaders to forge new connections & take advantage of in-person networking opportunities. Find out who you can connect with! 
|
|
| By Annalee Armstrong Novartis will no longer develop an ex vivo sickle cell disease program that was part of an older deal with Intellia, and the gene editing biotech’s CEO John Leonard thinks he knows why. |
|
|
|
By Max Bayer Moderna spent much of its fourth-quarter earnings call reassuring investors that its flu vaccine is still on an approval pathway after lukewarm phase 3 data dinged the company’s hot streak. |
By James Waldron Migraine therapy maker Impel Pharmaceuticals, psychedelics-focused Cybin and cancer and immuno-inflammatory-orientated EQRx are the latest biotechs handing out pink slips to employees as the flood of layoffs continues in the industry. |
Sponsored by Ocugen Ocugen remains diligent in developing innovative COVID-19 vaccine options—including a non-mRNA injectable and next-gen inhaled vaccine—to meet the current need and prepare for an annual booster strategy. |
|
April 3 - 4, 2023 | San Diego, CA The only west coast event exclusively for life science communicators to share best practices, benchmarks, and tools, as well as network with peers. Register by March 10th for the best Rate! 
|
|
By Annalee Armstrong Prilenia Therapeutics’ amyotrophic lateral sclerosis (ALS) therapy did not improve disease severity, but the biotech is pointing to “positive trends” from an exploratory analysis, suggesting that some patients' experienced a slower decline. |
By Nick Paul Taylor Jounce Therapeutics is cashing out. Despite having more than $150 million in the bank, the struggling biotech has decided it lacks the means to advance its clinical candidates, leading it to lay off 57% of its staff and enter into a reverse merger with Redx Pharma. |
By Gabrielle Masson Capsida Biotherapeutics is stepping beyond neurodegenerative conditions, diving into the world of eye disease with an AbbVie expansion pact for three new gene medicine targets. |
By Annalee Armstrong Graphite Bio is writing off a sickle cell therapy once heralded as a potential cure and cutting half its staff—including two executives—after a review of the business. |
By Nick Paul Taylor AstraZeneca is doubling down on the hot cancer target Claudin18.2, paying KYM Biosciences $63 million upfront for the global rights to an early-phase antibody-drug conjugate. The deal comes 10 months after the Big Pharma entered the space by paying $25 million upfront for a bispecific antibody. |
By Annalee Armstrong After ending all cardiology work in the wake of a failed phase 3 trial, Quantum Genomics is now reorganizing its board of directors, restructuring staff and again conducting a strategic review. |
By Gabrielle Masson Just a few months after discontinuing its most advanced pipeline asset, BioCryst Pharmaceuticals is now delaying testing of its only remaining clinical candidate. |
By James Waldron The latest example of a biotech-to-biotech merger sees Infinity Pharmaceuticals subsumed by MEI Pharma to create a combined company that will focus on Infinity’s lead asset along with two candidates from MEI. |
By Gabrielle Masson After a rocky 2022 for VBL Therapeutics, the biotech is merging with Notable Labs, a cancer-focused platform company that just pulled in $10.3 million from investors. |
By Joseph Keenan The U.K. government has name James O’Shaughnessy, a former health minister, to lead an independent review of the state of commercial clinical trials in the country. |
By Joseph Keenan London-based private equity firm Apax Partners has taken a majority stake in Porsolt and expects to grow the French CRO by increasing staff as much as 40% in the next four years. |
By Angus Liu Despite new phase 3 data for Eisai's Leqembi, the Centers for Medicare & Medicaid Services doesn't think there is enough evidence to reconsider a restrictive coverage policy for anti-amyloid Alzheimer's drugs. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the intense patent fight between Moderna and Pfizer-BioNTech around the mRNA technology used in their COVID-19 vaccines. We also talk about negotiating vaccine contracts via text messages, one of the biggest medtech deals of the year and other top headlines from this week. |
|
|---|
|
|
Research Like many top 10 and global pharma companies, an H1 client needed to diversify both its patient outreach and site investigator profiles for upcoming trials. Sponsored by: H1 |
Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
Whitepaper This paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
Whitepaper Exploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
Whitepaper Learn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Research Learn more on Catalent’s step-wise approach for the definition and execution of Process Characterization for the production of a monoclonal antibody for late phase process characterization and development. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
